上海医药
(601607)
| 流通市值：344.78亿 | | | 总市值：661.04亿 |
| 流通股本：19.32亿 | | | 总股本：37.03亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 30,040,144,079.63 | 30,517,706,443.04 | 29,263,734,941.59 | 31,337,367,133.62 |
| 衍生金融资产 | 1,596,097.37 | 2,596,393.11 | 6,371,535.14 | 3,436,387.25 |
| 应收票据及应收账款 | 82,940,797,362.36 | 74,842,530,072.65 | 77,427,177,737.01 | 78,823,719,484.03 |
| 其中：应收票据 | 1,694,769,858.77 | 1,908,648,955.48 | 1,268,588,471.74 | 1,409,207,805.83 |
| 应收账款 | 81,246,027,503.59 | 72,933,881,117.17 | 76,158,589,265.27 | 77,414,511,678.2 |
| 应收款项融资 | 2,314,411,123.29 | 2,320,106,012.96 | 1,941,354,874.99 | 1,562,015,687.9 |
| 预付款项 | 7,201,196,074.37 | 3,190,044,307.4 | 5,748,574,702.41 | 3,660,387,849.29 |
| 其他应收款合计 | 2,958,949,690.25 | 3,381,133,896.89 | 2,732,901,513.66 | 3,528,810,863.86 |
| 应收股利 | 239,151,615.4 | 239,065,993.48 | 391,138,217.3 | - |
| 存货 | 33,838,090,831.88 | 36,623,393,930.07 | 35,047,634,569.51 | 33,146,468,526.75 |
| 一年内到期的非流动资产 | 53,719,083.58 | 77,420,057.49 | 92,994,850.92 | 156,639,693.53 |
| 其他流动资产 | 921,439,376.62 | 1,326,776,412.93 | 964,465,989.39 | 1,124,275,094.46 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 167,405,500,979.62 | 162,433,862,348.46 | 164,628,820,577.63 | 164,781,723,168.36 |
| 非流动资产: | | | | |
| 长期应收款 | 225,742,256.59 | 227,939,569.6 | 199,089,327.03 | 200,858,612.45 |
| 长期股权投资 | 8,554,441,849.79 | 8,351,910,110.17 | 8,553,478,653.69 | 8,578,375,061.13 |
| 其他权益工具投资 | 66,122,515.83 | 55,416,725.2 | 53,797,240.28 | 56,382,940.45 |
| 其他非流动金融资产 | 2,193,496,868.53 | 2,195,371,867.75 | 2,124,808,342.06 | 2,168,130,907.7 |
| 投资性房地产 | 336,475,559.79 | 314,673,077.66 | 298,035,243.87 | 240,057,047.31 |
| 固定资产 | 11,932,590,285.81 | 12,155,054,666.68 | 11,123,260,339.84 | 11,307,368,958.74 |
| 在建工程 | 4,203,714,978.23 | 3,569,629,053.37 | 3,972,503,532.19 | 3,471,455,091.66 |
| 生产性生物资产 | 135,967,282.47 | 133,427,150.06 | 133,930,478.65 | 135,248,608.4 |
| 使用权资产 | 2,072,619,147.12 | 2,148,311,132.06 | 1,869,390,443.63 | 1,921,753,934.96 |
| 无形资产 | 5,882,602,167.64 | 6,050,835,947.46 | 5,989,554,088.04 | 6,120,506,873.42 |
| 开发支出 | 306,865,862.17 | 310,509,650.32 | 376,211,682.19 | 363,918,634.14 |
| 商誉 | 11,389,451,260.29 | 11,393,332,202.2 | 11,382,665,847.57 | 11,386,502,052.4 |
| 长期待摊费用 | 460,967,672.21 | 474,711,155.94 | 509,528,445.61 | 517,065,043.67 |
| 递延所得税资产 | 1,865,602,007.62 | 1,716,858,058.26 | 1,555,089,777.25 | 1,599,206,373.65 |
| 其他非流动资产 | 384,796,050.71 | 440,691,051.61 | 376,216,378.09 | 469,151,530.02 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 50,011,455,764.8 | 49,538,671,418.34 | 48,517,559,819.99 | 48,535,981,670.1 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 217,416,956,744.42 | 211,972,533,766.8 | 213,146,380,397.62 | 213,317,704,838.46 |
| 流动负债: | | | | |
| 短期借款 | 37,410,464,967.73 | 35,560,499,735.45 | 35,083,519,738.09 | 33,724,407,922.6 |
| 衍生金融负债 | 1,325,977.1 | 2,316,492.78 | 110,151.54 | 1,257,403.45 |
| 应付票据及应付账款 | 57,352,454,485.76 | 54,632,454,266.76 | 58,908,747,351.68 | 56,164,149,404.91 |
| 其中：应付票据 | 6,285,050,477.84 | 6,717,443,536.29 | 6,645,105,338.81 | 6,113,077,717.45 |
| 应付账款 | 51,067,404,007.92 | 47,915,010,730.47 | 52,263,642,012.87 | 50,051,071,687.46 |
| 合同负债 | 1,600,676,575.84 | 1,970,690,132.08 | 973,566,740.96 | 1,437,890,005.81 |
| 应付职工薪酬 | 1,304,345,917.97 | 1,783,979,964.7 | 1,400,167,377.38 | 1,413,278,642.49 |
| 应交税费 | 1,234,684,244.17 | 1,217,172,193.69 | 1,041,135,511.38 | 1,295,354,617.09 |
| 其他应付款合计 | 16,618,535,528.09 | 17,949,353,893.39 | 15,915,592,741.64 | 19,872,775,008.53 |
| 应付股利 | 245,171,287.95 | 247,130,022.22 | 319,736,981.8 | - |
| 一年内到期的非流动负债 | 3,571,794,964.57 | 2,963,475,811.09 | 2,937,610,462.72 | 4,234,825,090.02 |
| 其他流动负债 | 6,179,146,404.34 | 6,291,936,544.95 | 6,169,225,006.34 | 6,195,633,456 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 125,273,429,065.57 | 122,371,879,034.89 | 122,429,675,081.73 | 124,339,571,550.9 |
| 非流动负债: | | | | |
| 长期借款 | 6,620,983,465.48 | 5,786,154,730.58 | 7,487,613,491.5 | 6,869,962,559.2 |
| 租赁负债 | 1,514,473,037.53 | 1,550,076,681.63 | 1,312,971,609.45 | 1,322,310,985.71 |
| 长期应付款 | 9,887,509.06 | 8,163,467.74 | 8,121,514.2 | 8,128,733.7 |
| 长期应付职工薪酬 | 37,098,179.18 | 38,884,169.72 | 38,350,727.06 | 38,785,409.09 |
| 预计负债 | 35,879,341.68 | 39,585,088.27 | 26,798,144.36 | 26,255,410.24 |
| 递延收益 | 633,155,235.33 | 633,481,321.72 | 538,353,472.27 | 562,757,451.14 |
| 递延所得税负债 | 998,506,366.24 | 1,015,820,143.36 | 928,282,197.38 | 985,583,568.96 |
| 其他非流动负债 | 207,897,226.75 | 202,396,163.96 | 232,580,587.15 | 221,872,282.57 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,057,880,361.25 | 9,274,561,766.98 | 10,573,071,743.37 | 10,035,656,400.61 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 135,331,309,426.82 | 131,646,440,801.87 | 133,002,746,825.1 | 134,375,227,951.51 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,703,301,054 | 3,703,301,054 | 3,703,301,054 | 3,703,212,524 |
| 资本公积 | 29,188,056,964.82 | 29,187,649,155.53 | 29,168,809,495.26 | 29,164,167,422.22 |
| 其他综合收益 | -501,002,596.82 | -496,089,430.12 | -538,759,062.41 | -498,240,910.42 |
| 盈余公积 | 2,306,949,383.63 | 2,306,949,383.63 | 2,158,807,271.16 | 2,158,807,271.16 |
| 未分配利润 | 35,364,610,442.49 | 33,822,332,888.31 | 34,017,650,896.04 | 32,830,702,078.17 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 70,061,915,248.12 | 68,524,143,051.35 | 68,509,809,654.05 | 67,358,648,385.13 |
| 少数股东权益 | 12,023,732,069.48 | 11,801,949,913.58 | 11,633,823,918.47 | 11,583,828,501.82 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 82,085,647,317.6 | 80,326,092,964.93 | 80,143,633,572.52 | 78,942,476,886.95 |
| 负债和股东权益合计 | 217,416,956,744.42 | 211,972,533,766.8 | 213,146,380,397.62 | 213,317,704,838.46 |
| 公告日期 | 2024-04-27 | 2024-03-29 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |